CME Group’s (CME) “Buy” Rating Reaffirmed at Jefferies Group
CME Group Inc. (NASDAQ:CME)‘s stock had its “buy” rating reiterated by analysts at Jefferies Group in a research note issued on Thursday. They presently have a $118.00 price target on the stock. Jefferies Group’s target price suggests a potential upside of 13.17% from the stock’s current price.
CME has been the topic of several other research reports. Deutsche Bank AG lifted their price target on CME Group from $115.00 to $116.00 and gave the company a “buy” rating in a research note on Wednesday, October 5th. JPMorgan Chase & Co. set a $116.00 price objective on CME Group and gave the company a “buy” rating in a report on Monday, September 12th. Zacks Investment Research raised CME Group from a “sell” rating to a “hold” rating in a report on Thursday, June 30th. Barclays PLC cut their price objective on CME Group from $100.00 to $99.00 and set an “equal weight” rating on the stock in a report on Friday, July 29th. Finally, Keefe, Bruyette & Woods raised their price objective on CME Group from $99.00 to $103.00 and gave the company a “market perform” rating in a report on Friday, July 29th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $103.27.
CME Group (NASDAQ:CME) traded down 0.68% during mid-day trading on Thursday, reaching $103.56. 330,843 shares of the company were exchanged. CME Group has a 12 month low of $81.87 and a 12 month high of $110.35. The stock’s 50-day moving average is $106.54 and its 200-day moving average is $99.60. The company has a market cap of $35.09 billion, a P/E ratio of 26.15 and a beta of 0.83.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/13/cme-groups-cme-buy-rating-reaffirmed-at-jefferies-group.html
CME Group (NASDAQ:CME) last issued its quarterly earnings results on Thursday, July 28th. The company reported $1.14 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.03. CME Group had a return on equity of 6.83% and a net margin of 38.22%. The company had revenue of $906 million for the quarter, compared to analyst estimates of $897.84 million. During the same quarter last year, the company posted $0.95 EPS. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. Equities analysts expect that CME Group will post $4.43 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Monday, September 26th. Investors of record on Friday, September 9th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 2.30%. The ex-dividend date of this dividend was Wednesday, September 7th. CME Group’s payout ratio is 60.61%.
In related news, insider Hilda Harris Piell sold 893 shares of the business’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $110.00, for a total value of $98,230.00. Following the completion of the sale, the insider now directly owns 29,125 shares of the company’s stock, valued at approximately $3,203,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director James E. Oliff sold 1,000 shares of the business’s stock in a transaction dated Friday, July 15th. The shares were sold at an average price of $102.30, for a total value of $102,300.00. The disclosure for this sale can be found here. 0.61% of the stock is owned by corporate insiders.
A number of hedge funds have recently modified their holdings of CME. Hudock Capital Group LLC raised its stake in shares of CME Group by 0.7% in the second quarter. Hudock Capital Group LLC now owns 3,706 shares of the company’s stock worth $360,000 after buying an additional 24 shares during the last quarter. Windward Capital Management Co. CA raised its stake in shares of CME Group by 1.0% in the second quarter. Windward Capital Management Co. CA now owns 2,626 shares of the company’s stock worth $256,000 after buying an additional 25 shares in the last quarter. Gofen & Glossberg LLC IL raised its stake in shares of CME Group by 0.4% in the second quarter. Gofen & Glossberg LLC IL now owns 7,323 shares of the company’s stock worth $713,000 after buying an additional 26 shares in the last quarter. Beacon Financial Group raised its stake in shares of CME Group by 0.8% in the second quarter. Beacon Financial Group now owns 4,525 shares of the company’s stock worth $435,000 after buying an additional 38 shares in the last quarter. Finally, Pekin Singer Strauss Asset Management IL raised its stake in shares of CME Group by 0.3% in the second quarter. Pekin Singer Strauss Asset Management IL now owns 13,811 shares of the company’s stock worth $1,345,000 after buying an additional 39 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.
CME Group Company Profile
CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.
Receive News & Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.